Company: Quanterix Corporation
Symbol: QTRX
Description: They are a life sciences company that has developed a next generation, ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics.
Shares: 3.34 million
Price Range: $14.00-$16.00
Trade Date: 12/7
Underwriter(s): J.P. Morgan, Leerink
Co-Manager(s): BTIG, Evercore ISI
Terms Added: 11-27-17
Business: Their platform enables customers to reliably detect protein biomarkers in extremely low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. It also allows researchers to define and validate the function of novel protein biomarkers that are only present in very low concentrations and have been discovered using technologies such as mass spectrometry. These capabilities provide customers with insight into the role of protein biomarkers in human health that has not been possible with other existing technologies and enable researchers to unlock unique insights into the continuum between health and disease. They believe this greater insight will enable the development of novel therapies and diagnostics and facilitate a paradigm shift in healthcare from an emphasis on treatment to a focus on earlier detection, monitoring, prognosis and, ultimately, prevention. They are currently focusing their platform on protein detection, which they believe is an area of significant unmet need and where they have significant competitive advantages. In addition to enabling new applications and insights in protein analysis, QTRX is also developing their Simoa technology to detect nucleic acids in biological samples.
Insider Buying: Certain of their existing shareholders, including certain of their directors and affiliates of their directors, and their affiliated entities have indicated an interest in purchasing an aggregate of up to approximately $30.0 million of their common shares in this offering at the initial public offering price per share.
Book-Building Status: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website.
Indicate with confidence, SUBSCRIBE today.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish